Skip to main content
NCBI home page
British Heart Journal logoLink to British Heart Journal
. 1995 Jan;73(1):41–48. doi: 10.1136/hrt.73.1.41

Activation and inhibition of the endogenous opioid system in human heart failure.

K G Oldroyd 1, C E Gray 1, R Carter 1, K Harvey 1, W Borland 1, G Beastall 1, S M Cobbe 1
PMCID: PMC483754  PMID: 7888260

Abstract

BACKGROUND--In a canine model of congestive heart failure beta endorphin concentrations were high and opioid receptor antagonists exerted beneficial haemodynamic effects. In humans previous studies have suggested that opioid peptides may modify the perception of breathlessness and fatigue in heart failure. METHODS--Plasma concentrations of beta endorphin were measured in patients with acute and chronic heart failure and cardiogenic shock. A subgroup of eight patients with New York Heart Association (NYHA) class III-IV heart failure was assessed for acute haemodynamic effects of naloxone, an opioid receptor antagonist. A separate group of 10 patients with class II-III heart failure, was randomised to a double blind placebo controlled study of the effects of intravenous naloxone on cardiopulmonary exercise performance. RESULTS--Plasma concentrations of beta endorphin were usually normal in patients with chronic heart failure and did not correlate with severity as assessed by NYHA class. In 29% of patients with acute heart failure and 71% of those with cardiogenic shock beta endorphin concentrations were high. The median concentration in the cardiogenic shock group was significantly higher than in either of the two heart failure groups and there was some evidence of a relation between beta endorphin concentrations and survival. At the doses tested, naloxone was unable to modify systemic haemodynamics, exercise performance, or symptoms in patients with chronic congestive heart failure. CONCLUSIONS--Circulating concentrations of beta endorphin are usually normal in patients with chronic congestive heart failure. Inhibition of the endogenous opioid system is unlikely to have therapeutic potential in heart failure.

Full text

PDF
41

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albeck H., Woodfield S., Kreek M. J. Quantitative and pharmacokinetic analysis of naloxone in plasma using high-performance liquid chromatography with electrochemical detection and solid-phase extraction. J Chromatogr. 1989 Mar 24;488(2):435–445. doi: 10.1016/s0378-4347(00)82967-9. [DOI] [PubMed] [Google Scholar]
  2. BARGER A. C., ROE B. B., RICHARDSON G. S. Relation of valvular lesions and of exercise to auricular pressure, work tolerance, and to development of chronic, congestive failure in dogs. Am J Physiol. 1952 May;169(2):384–399. doi: 10.1152/ajplegacy.1952.169.2.384. [DOI] [PubMed] [Google Scholar]
  3. Bach F. W., Fahrenkrug J., Jensen K., Dahlstrøm G., Ekman R. Plasma beta-endorphin during clinical and experimental ischaemic pain. Scand J Clin Lab Invest. 1987 Dec;47(8):751–758. [PubMed] [Google Scholar]
  4. Bland J. M., Altman D. G. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986 Feb 8;1(8476):307–310. [PubMed] [Google Scholar]
  5. Carr D. B., Bullen B. A., Skrinar G. S., Arnold M. A., Rosenblatt M., Beitins I. Z., Martin J. B., McArthur J. W. Physical conditioning facilitates the exercise-induced secretion of beta-endorphin and beta-lipotropin in women. N Engl J Med. 1981 Sep 3;305(10):560–563. doi: 10.1056/NEJM198109033051006. [DOI] [PubMed] [Google Scholar]
  6. Carr D. B., Bullen B. A., Skrinar G. S., Arnold M. A., Rosenblatt M., Beitins I. Z., Martin J. B., McArthur J. W. Physical conditioning facilitates the exercise-induced secretion of beta-endorphin and beta-lipotropin in women. N Engl J Med. 1981 Sep 3;305(10):560–563. doi: 10.1056/NEJM198109033051006. [DOI] [PubMed] [Google Scholar]
  7. Croog S. H., Levine S., Testa M. A., Brown B., Bulpitt C. J., Jenkins C. D., Klerman G. L., Williams G. H. The effects of antihypertensive therapy on the quality of life. N Engl J Med. 1986 Jun 26;314(26):1657–1664. doi: 10.1056/NEJM198606263142602. [DOI] [PubMed] [Google Scholar]
  8. Fan T. H., Liang C. S., Kawashima S., Banerjee S. P. Alterations in cardiac beta-adrenoceptor responsiveness and adenylate cyclase system by congestive heart failure in dogs. Eur J Pharmacol. 1987 Aug 11;140(2):123–132. doi: 10.1016/0014-2999(87)90798-9. [DOI] [PubMed] [Google Scholar]
  9. Farrell P. A., Gates W. K., Maksud M. G., Morgan W. P. Increases in plasma beta-endorphin/beta-lipotropin immunoreactivity after treadmill running in humans. J Appl Physiol Respir Environ Exerc Physiol. 1982 May;52(5):1245–1249. doi: 10.1152/jappl.1982.52.5.1245. [DOI] [PubMed] [Google Scholar]
  10. Gurll N. J., Reynolds D. G., Holaday J. W. Evidence for a role of endorphins in the cardiovascular pathophysiology of primate shock. Crit Care Med. 1988 May;16(5):521–530. doi: 10.1097/00003246-198805000-00011. [DOI] [PubMed] [Google Scholar]
  11. Imura H., Kato Y., Nakai Y., Nakao K., Tanaka I., Jingami H., Koh T., Yoshimasa T., Tsukada T., Suda M. Endogenous opioids and related peptides: from molecular biology to clinical medicine. The Sir Henry Dale lecture for 1985. J Endocrinol. 1985 Nov;107(2):147–157. doi: 10.1677/joe.0.1070147. [DOI] [PubMed] [Google Scholar]
  12. Jacob A. J., Boon N. A. HIV cardiomyopathy: a dark cloud with a silver lining? Br Heart J. 1991 Jul;66(1):1–2. doi: 10.1136/hrt.66.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kawashima S., Fukutake N., Nishian K., Asakuma S., Iwasaki T. Elevated plasma beta-endorphin levels in patients with congestive heart failure. J Am Coll Cardiol. 1991 Jan;17(1):53–58. doi: 10.1016/0735-1097(91)90703-c. [DOI] [PubMed] [Google Scholar]
  14. Kindman L. A., Fowler M. B. Hemodynamic effects of high dose naloxone in congestive heart failure. Am J Cardiol. 1989 Sep 1;64(8):542–544. doi: 10.1016/0002-9149(89)90439-6. [DOI] [PubMed] [Google Scholar]
  15. Liang C. S., Imai N., Stone C. K., Woolf P. D., Kawashima S., Tuttle R. R. The role of endogenous opioids in congestive heart failure: effects of nalmefene on systemic and regional hemodynamics in dogs. Circulation. 1987 Feb;75(2):443–451. doi: 10.1161/01.cir.75.2.443. [DOI] [PubMed] [Google Scholar]
  16. Lord J. A., Waterfield A. A., Hughes J., Kosterlitz H. W. Endogenous opioid peptides: multiple agonists and receptors. Nature. 1977 Jun 9;267(5611):495–499. doi: 10.1038/267495a0. [DOI] [PubMed] [Google Scholar]
  17. McConway M. G., Chapman R. S. Development and evaluation of a simple, direct, solid-phase radioimmunoassay of serum cortisol from readily available reagents. Clin Chim Acta. 1986 Jul 15;158(1):59–70. doi: 10.1016/0009-8981(86)90116-6. [DOI] [PubMed] [Google Scholar]
  18. Nicholson W. E., Davis D. R., Sherrell B. J., Orth D. N. Rapid radioimmunoassay for corticotropin in unextracted human plasma. Clin Chem. 1984 Feb;30(2):259–265. [PubMed] [Google Scholar]
  19. Northridge D. B., Grant S., Ford I., Christie J., McLenachan J., Connelly D., McMurray J., Ray S., Henderson E., Dargie H. J. Novel exercise protocol suitable for use on a treadmill or a bicycle ergometer. Br Heart J. 1990 Nov;64(5):313–316. doi: 10.1136/hrt.64.5.313. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Oldroyd K. G., Harvey K., Gray C. E., Beastall G. H., Cobbe S. M. Beta endorphin release in patients after spontaneous and provoked acute myocardial ischaemia. Br Heart J. 1992 Mar;67(3):230–235. doi: 10.1136/hrt.67.3.230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Oldroyd K. G., Hicks M. N., Cobbe S. M. Influence of hyperkalaemia and ischaemia on non-receptor-mediated cardiac electrophysiological effects of naloxone. Cardiovasc Res. 1993 Feb;27(2):296–303. doi: 10.1093/cvr/27.2.296. [DOI] [PubMed] [Google Scholar]
  22. Oldroyd K. G., Pye M. P., Ray S. G., Christie J., Ford I., Cobbe S. M., Dargie H. J. Effects of early captopril administration on infarct expansion, left ventricular remodeling and exercise capacity after acute myocardial infarction. Am J Cardiol. 1991 Sep 15;68(8):713–718. doi: 10.1016/0002-9149(91)90641-w. [DOI] [PubMed] [Google Scholar]
  23. Paterson S. J., Robson L. E., Kosterlitz H. W. Classification of opioid receptors. Br Med Bull. 1983 Jan;39(1):31–36. doi: 10.1093/oxfordjournals.bmb.a071787. [DOI] [PubMed] [Google Scholar]
  24. Rahkila P., Hakala E., Alén M., Salminen K., Laatikainen T. Beta-endorphin and corticotropin release is dependent on a threshold intensity of running exercise in male endurance athletes. Life Sci. 1988;43(6):551–558. doi: 10.1016/0024-3205(88)90158-0. [DOI] [PubMed] [Google Scholar]
  25. Sagy M., Shavit G., Oron Y., Vidne B. A., Gitter S., Sarne Y. Nonopiate effect of naloxone on cardiac muscle contractility. J Cardiovasc Pharmacol. 1987 Jun;9(6):682–685. doi: 10.1097/00005344-198706000-00007. [DOI] [PubMed] [Google Scholar]
  26. Sakamoto S., Stone C. K., Woolf P. D., Liang C. S. Opiate receptor antagonism in right-sided congestive heart failure. Naloxone exerts salutary hemodynamic effects through its action on the central nervous system. Circ Res. 1989 Jul;65(1):103–114. doi: 10.1161/01.res.65.1.103. [DOI] [PubMed] [Google Scholar]
  27. Sheps D. S., Adams K. F., Hinderliter A., Price C., Bissette J., Orlando G., Margolis B., Koch G. Endorphins are related to pain perception in coronary artery disease. Am J Cardiol. 1987 Mar 1;59(6):523–527. doi: 10.1016/0002-9149(87)91161-1. [DOI] [PubMed] [Google Scholar]
  28. Starling M. R., Crawford M. H., Sorensen S. G., Levi B., Richards K. L., O'Rourke R. A. Comparative accuracy of apical biplane cross-sectional echocardiography and gated equilibrium radionuclide angiography for estimating left ventricular size and performance. Circulation. 1981 May;63(5):1075–1084. doi: 10.1161/01.cir.63.5.1075. [DOI] [PubMed] [Google Scholar]
  29. Vargish T., Beamer K. Hemodynamic effects of naloxone in early canine hypovolemic shock. Circ Shock. 1985;17(1):45–57. [PubMed] [Google Scholar]
  30. Vozeh S., Schmidlin O., Taeschner W. Pharmacokinetic drug data. Clin Pharmacokinet. 1988 Oct;15(4):254–282. doi: 10.2165/00003088-198815040-00005. [DOI] [PubMed] [Google Scholar]
  31. Wilson R. C., Jones P. W. A comparison of the visual analogue scale and modified Borg scale for the measurement of dyspnoea during exercise. Clin Sci (Lond) 1989 Mar;76(3):277–282. doi: 10.1042/cs0760277. [DOI] [PubMed] [Google Scholar]
  32. Zubenko G. S., Nixon R. A. Mood-elevating effect of captopril in depressed patients. Am J Psychiatry. 1984 Jan;141(1):110–111. doi: 10.1176/ajp.141.1.110. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES